Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 150 participants.

Also called NCT07908225

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07908225
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07908225. Allocation not applicable; no masking; primary purpose treatment. Start 2021-09-10 (actual); primary completion 2024-02-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
Condition
Aortic Stenosis
Lead sponsor
Peijia Medical Technology (Suzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07908225
Content hash
dd0648adbf955ae889738cb513fdd1a7436aa44f884830a115daf1fd422d0ab9